India · Delayed Price · Currency is INR Alkem Laboratories Earnings Call Transcripts
Fiscal Year 2026
-
Record EBITDA and double-digit revenue growth achieved, driven by strong India and international performance, especially in chronic therapies and new launches like semaglutide. Margin guidance for FY27 is 20-21%, with ongoing cost pressures and a focus on execution and portfolio expansion.
-
Q3 FY26 saw 10.7% revenue growth and stable margins, with strong international sales and robust chronic segment performance. Major Medtech acquisition (Occlutech) positions the company for global expansion, targeting 14% CAGR and higher EBITDA margins.
-
Q2 FY26 saw record revenue and strong growth across India, US, and international markets, with EBITDA up 22.3% YoY and net profit up 11.1% YoY. Guidance remains for double-digit growth and margin expansion, with new launches and investments in CDMO and MedTech supporting future performance.
-
Q1 FY 2026 saw double-digit revenue and profit growth, margin expansion, and outperformance in key therapies. Management maintains guidance, expects continued margin improvement, and is investing in new businesses and acquisitions to drive future growth.
Fiscal Year 2025
-
Q4 FY25 saw strong India business growth and improved margins, with FY25 revenue up 2.3% and net profit up 20.6% year-over-year. FY26 guidance includes stable EBITDA margins, mid-single-digit US growth, and increased R&D and CapEx. Domestic and ROW markets are expected to outperform, while new segments will incur initial losses.
-
Q3 FY25 saw modest revenue growth and strong margin expansion, driven by higher-margin products and cost efficiencies. Two acquisitions in dermato-cosmetology and orthopedics were announced, and guidance for FY25 EBITDA margin remains at 19%.
-
Profitability improved with EBITDA margin rising to 21.1% in H1 FY25, driven by cost controls and a high-margin product mix. Domestic growth guidance remains at 8%-9%, while US business faces mid-single-digit decline but expects H2 recovery. CapEx and cash reserves support strategic expansion.
-
EBITDA margin rose to 20.1% in Q1 FY25, driven by product mix, cost control, and API price benefits. Full-year EBITDA margin guidance remains at ~18% due to investments in biosimilars, CDMO, and medical devices, with gross margin expected to improve to 62%-62.5%.